πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 750 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11365230

Compositions comprising lentiviral vectors expressing IL-12 and methods of use thereof

IMMUNE DESIGN CORP. Β· Granted Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11357839

Brachyury protein, non-poxvirus non-yeast vectors encoding Brachyury protein, and their us

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11352639

Gene therapy based on vector VTVAF17

OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTJU β€œALLEL TSENTR INNOVATSIONNYKH BIOTEKHNOLOGY” Β· Granted Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11351177

Corticotropin releasing factor receptor antagonists

SPRUCE BIOSCIENCES, INC. Β· Granted Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11344557

Corticotropin releasing factor receptor antagonists

SPRUCE BIOSCIENCES, INC. Β· Granted Tue May 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11345928

Modified immunization vectors

THE ARIZONA BOARD OF REGENTS Β· Granted Tue May 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11332727

Method for reducing an immune response by administering an immune evading adeno-associated

The Regents of the University of California Β· Granted Tue May 17 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 12 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11311549

Corticotropin releasing factor receptor antagonists

SPRUCE BIOSCIENCES, INC. Β· Granted Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11299533

Purification of factor VIII subspecies

Takeda Pharmaceutical Company Limited Β· Granted Tue Apr 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11286528

Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VI

BIOVERATIV THERAPEUTICS INC. Β· Granted Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11273182

Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal

Takeda Pharmaceutical Company Limited Β· Granted Tue Mar 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11274294

TAL effector-mediated DNA modification

Regents of the University of Minnesota Β· Granted Tue Mar 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11274282

Vesicular stomatitis vectors encoding Crimean-Congo hemorrhagic fever antigen

The Board of Regents of the University of Texas System Β· Granted Tue Mar 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11266720

Factor VIII-FC chimeric and hybrid polypeptides, and methods of use thereof

BIOVERATIV THERAPEUTICS INC. Β· Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11267782

Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2Ξ± inhibitors

NIKANG THERAPEUTICS, INC. Β· Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11266724

Modified factor VII polypeptides for subcutaneous administration and on-demand treatment

Catalyst Biosciences, Inc. Β· Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11261237

Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating n

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA Β· Granted Tue Mar 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11254731

Viral vectors encoding recombinant FVIII variants with increased expression for gene thera

Takeda Pharmaceutical Company Limited Β· Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11254739

Anti-human migration stimulating factor (MSF) and uses thereof

HUMANITAS MIRASOLE S.P.A. Β· Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11241478

Adenovirus-associated viral vectors for expressing variants of tetratricopeptide repeat (T

Northwestern University Β· Granted Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11236100

Modulators of eukaryotic initiation factor 2B, compositions and methods

DENALI THERAPEUTICS INC. Β· Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11225514

Nanobodies against cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory f

The Regents of the University of California Β· Granted Tue Jan 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11203749

Factor VII polypeptides that are modified and uses thereof

Catalyst Biosciences, Inc. Β· Granted Tue Dec 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11192936

Factor VIII chimeric proteins and uses thereof

BIOVERATIV THERAPEUTICS INC. Β· Granted Tue Dec 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted